The center coordinator of each participating medical institution collected and compiled clinical data in an online case report database. The collected data included the following: (i) MK-2206 in vitro patient and disease characteristics, i.e. patient demographic data, type of infection (nosocomial or community-acquired), severity criteria, and previous antibiotic therapy administered in the 7 days preceding surgery; (ii) origin of infection, surgical procedures

performed, and antibiotic therapies administered; and (iii) microbiological data, i.e. identification of bacteria and microorganismal pathogens within the peritoneal fluid, the identification of yeasts (if present), and the antibiotic susceptibilities of bacterial isolates. This observational study did not attempt to change or modify the laboratory or clinical practices of the participating physicians or their respective institutions, and it did not require

informed consent or formal approval by an Ethics Committee. A Scientific Committee was established to impartially assess the objectives, methodology, and overall scientific quality of the project. The study was monitored by the coordination center, which processed and verified missing or unclear data submitted to the central database. Statistical analysis was performed using STATA® statistical software. Results Patients 2,152 patients with a mean age of 53.8 years (range 4–98) were enrolled in the CIAO Study. 996 patients (46.3%) were women and 1,156 (53.7%) were men. Among these Bcl-2 inhibitor patients, 1,701 (79%) were affected by community-acquired IAIs while the remaining 451 (21%) see more suffered from heathcare-associated infections. Intraperitoneal specimens were collected from 1,338 (62.2%) of the enrolled patients. 787 patients

(36.5%) were affected by generalized peritonitis while 1,365 (63.5%) suffered from localized peritonitis or abscesses. 282 patients (13.1%) were admitted in critical condition (severe sepsis/septic shock). Tables 1, 2 overviews the clinical findings and radiological assessments recorded upon patient admission. Table 1 Clinical Findings Clinical findings Oxalosuccinic acid Patients   n° (%) Abdominal pain 271 (12.6) Abdominal pain, abdominal rigidity 192 (8.9%) Abdominal pain, abdominal rigidità, T>38°C or <36°C, WBC >12,000 or < 4,000 366 (17%) Abdominal pain, abdominal rigidity, T>38°C or <36°C, 70 (3.2) Abdominal pain, abdominal rigidity, WBC >12,000 or < 4,000 445 (20.7%) Abdominal pain, T>38°C or <36°C, 71 (3.3%) Abdominal pain, T>38°C or <36°C, WBC >12,000 or < 4,000 235 (10.9%) Abdominal pain, WBC >12,000 or < 4,000 325 (15.1) T>38°C or <36°C 15 (0.7 %) T>38°C or <36°C, WBC >12,000 or < 4,000 45 (2.0%) Abdominal rigidity, WBC >12,000 or < 4,000 15 (0.7%) Abdominal rigidity 15 (0.7%) Abdominal rigidity, T>38°C or <36°C 22 (1%) WBC >12,000 or < 4,000 32 (1.5%) Not reported 33 (1.